Search

Displaying results 3241 - 3250 of 6196 in total
  1. Drug

    Clevidipine

    go.drugbank.com/drugs/DB04920
    ApprovedInvestigational

    Clevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option.

  2. Drug

    Xamoterol

    go.drugbank.com/drugs/DB13781
    Approved

    It modulates the sympathetic control of the heart but has no agonist action on β2-adrenoceptors.

  3. Drug

    Perfluorohexyloctane

    go.drugbank.com/drugs/DB17823
    ApprovedInvestigational

    [L46491] It is an inert, slightly amphiphilic compound. … [A259741] It was approved by the FDA on May 18, 2023 for the treatment of dry eye disease.[L46536]

  4. Drug

    Monobenzone

    go.drugbank.com/drugs/DB00600
    ApprovedWithdrawn

    It exerts a depigmenting effect on skin of mammals by increasing the excretion of melanin from the melanocytes. It may also cause destruction of melanocytes and permanent depigmentation.

  5. Drug

    BW-A 58C

    go.drugbank.com/drugs/DB06740
    Experimental

    metabolite in man in vivo and also in human liver microsomes, where this is catalysed primarily by a 54 kDa CYP2C9 form of cytochrome P450, P450hB20-27. … BW-A 58C, also known as 2-(4-tert-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone, is an experimental naphthoquinone antimalarial drug which undergoes extensive alkyl hydroxylation to a single t-butylhydroxy

  6. Drug

    Axatilimab

    go.drugbank.com/drugs/DB16388
    ApprovedInvestigational

    [L51194] The mainstay of cGVHD treatment are systemic corticosteroids, but they are ineffective in 30-50% of cases. … [A264309] Axatilimab was approved by the FDA in August 2024 for the third-line treatment of cGVHD.

  7. Drug

    MPI-674

    go.drugbank.com/drugs/DB05749
    Experimental

    MPI-674 is an aromatase inhibitor (AI) with a well-established, multi-year chronic safety and tolerability profile. … AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and inhibiting the enzyme aromatase, which is responsible for converting certain hormones to estrogen.

  8. Drug

    Elesclomol

    go.drugbank.com/drugs/DB05719
    Investigational

    It is being developed by Synta Pharmaceuticals. … Elesclomol is a novel, injectable, drug candidate that kills cancer cells by elevating oxidative stress levels beyond a breaking point, triggering programmed cell death.

  9. Drug

    Multipotent adult arogenitor cells

    go.drugbank.com/drugs/DB15742
    Investigational

    Additional benefits of MultiStem include their low immunogenicity, meaning they can be administered without tissue matching or concurrent immunosuppressive agents. … MultiStem is an intravenously-administered, off-the-shelf proprietary product developed which comprises Multipotent Adult Progenitor Cells (MAPCs).

  10. Drug

    SPC2968

    go.drugbank.com/drugs/DB06351
    Investigational

    SPC2968 is a synthetic antisense oligodeoxynucleotide targeting hypoxia-inducible factor-1alpha (HIF-1alpha). It was under investigation in clinical trial NCT02564614 (A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic ...